{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:14:55Z","timestamp":1792682095820,"version":"4.5.0"},"reference-count":137,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Intra-abdominal infections (IAIs) remain among the most challenging problems in surgical clinical practice. They range from uncomplicated appendicitis to life-threatening peritonitis, demanding rapid diagnosis, timely source control, and appropriate antibiotic therapy. Antibiotics are crucial to manage patients with complicated IAIs. Antibiotics should always be prescribed appropriately, ensuring the correct spectrum, timing, duration, and dosage. Appropriate prescribing within hospitals enhances treatment success and patient safety, while also reducing the risk of opportunistic infections such as Clostridioides difficile and lowering the likelihood of selecting resistant pathogens. Over recent decades, antimicrobial resistance has escalated into a worldwide public health threat. The rapid rise in multidrug-resistant organisms, especially Gram-negative bacteria, has created a pressing global concern. The objective of this narrative review is to describe (a) when antibiotics should be used in patients with IAIs; (b) which antibiotics should be selected in patients with IAIs; (c) how they should be managed in patients with IAIs; and (d) how long they should be administered in patients with IAIs.<\/jats:p>","DOI":"10.3390\/antibiotics14111127","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:56:45Z","timestamp":1762513005000},"page":"1127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibiotics for Intra-Abdominal Infections: When, Which, How and How Long?"],"prefix":"10.3390","volume":"14","author":[{"given":"Massimo","family":"Sartelli","sequence":"first","affiliation":[{"name":"Department of General Surgery, Macerata Hospital, 62100 Macerata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Macerata Hospital, 62100 Macerata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Labricciosa","sequence":"additional","affiliation":[{"name":"Global Alliance for Infections in Surgery, 62100 Macerata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13017-024-00551-w","article-title":"Management of intra-abdominal infections: Recommendations by the Italian council for the optimization of antimicrobial use","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J. Emerg. Surg."},{"key":"ref_2","first-page":"CD001439","article-title":"Antibiotics versus placebo for prevention of postoperative infection after appendicectomy","volume":"3","author":"Andersen","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s00268-012-1572-6","article-title":"Role of antibiotic therapy in mild acute calculus cholecystitis: A prospective randomized controlled trial","volume":"36","author":"Mazeh","year":"2012","journal-title":"World J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2014.7586","article-title":"Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis: A randomized clinical trial","volume":"312","author":"Regimbeau","year":"2014","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/bjs.10147","article-title":"Meta-analysis of antibiotics versus appendicectomy for non-perforated acute appendicitis","volume":"103","author":"Sallinen","year":"2016","journal-title":"Br. J. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2015.6154","article-title":"Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis: The APPAC Randomized Clinical Trial","volume":"313","author":"Salminen","year":"2015","journal-title":"JAMA"},{"key":"ref_7","first-page":"e52697","article-title":"Conservative Versus Surgical Management of Acute Appendicitis: A Systematic Review","volume":"16","author":"Chin","year":"2024","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/hpb.12449","article-title":"Delayed laparoscopic cholecystectomy increases the total hospital stay compared to an early laparoscopic cholecystectomy after acute cholecystitis: An updated meta-analysis of randomized controlled trials","volume":"17","author":"Menahem","year":"2015","journal-title":"HPB"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1007\/s00464-018-6400-0","article-title":"Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: An up-to-date meta-analysis of randomized controlled trials","volume":"32","author":"Lyu","year":"2018","journal-title":"Surg. Endosc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13017-021-00360-5","article-title":"Timing of early laparoscopic cholecystectomy for acute calculous cholecystitis: A meta-analysis of randomized clinical trials","volume":"16","author":"Borzellino","year":"2021","journal-title":"World J. Emerg. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.2022.2350","article-title":"Acute Cholecystitis: A Review","volume":"327","author":"Gallaher","year":"2022","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1749-7922-10-3","article-title":"A proposal for a CT driven classification of left colon acute diverticulitis","volume":"10","author":"Sartelli","year":"2015","journal-title":"World J. Emerg. Surg."},{"key":"ref_13","first-page":"e92378","article-title":"Antibiotic Prescription for Acute Diverticulitis: Evaluation of Compliance with National Guidelines","volume":"17","author":"Mateen","year":"2025","journal-title":"Cureus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/bjs.8688","article-title":"AVODStudy Group Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis","volume":"99","author":"Chabok","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/DCR.0000000000000579","article-title":"Symptomatic treatment for uncomplicated acute diverticulitis: A prospective cohort study","volume":"59","author":"Mali","year":"2016","journal-title":"Dis. Colon Rectum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/bjs.10309","article-title":"Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis","volume":"104","author":"Daniels","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.03935-14","article-title":"Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis","volume":"59","author":"Cain","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/infdis\/jiaa146","article-title":"A critical analysis of the literature on time-to-antibiotics in suspected sepsis","volume":"222","author":"Weinberger","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to Treatment and Mortality during Mandated Emergency Care for Sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1308\/003588404323043346","article-title":"Intra-operative culture in appendicitis: Traditional practice challenged","volume":"86","author":"Gladman","year":"2004","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijsu.2010.06.016","article-title":"Peritoneal fluid culture in appendicitis: Review in changing times","volume":"8","author":"Davies","year":"2010","journal-title":"Int. J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10096-004-1199-0","article-title":"Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery","volume":"23","author":"Krobot","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Silva-Nunes, J., and Cardoso, T. (2019). Intra-abdominal infections: The role of different classifications on the selection of the best antibiotic treatment. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4604-0"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jac\/dkp005","article-title":"Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study","volume":"63","author":"Montravers","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/00365540701449377","article-title":"Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain","volume":"39","author":"Tellado","year":"2007","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1017\/S0266462306051063","article-title":"Importance of appropriateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections","volume":"22","author":"Castells","year":"2006","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2125.2005.02443.x","article-title":"Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs","volume":"60","author":"Sturkenboom","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jeon, H.G., Ju, H.U., Kim, G.Y., Jeong, J., Kim, M.H., and Jun, J.B. (2014). Bacteriology and changes in antibiotic susceptibility in adults with community-acquired perforated appendicitis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111144"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10096-011-1357-0","article-title":"Initial microbial spectrum in severe secondary peritonitis and relevance for treatment","volume":"31","author":"Kiewiet","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/sur.2020.001","article-title":"Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Anti-Enterococcal Therapy for Intra-Abdominal Infection","volume":"22","author":"Zhang","year":"2021","journal-title":"Surg. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/sur.2007.041","article-title":"Choosing antibiotics for intra-abdominal infections: What do we mean by \u201chigh risk\u201d?","volume":"10","author":"Swenson","year":"2009","journal-title":"Surg. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000526785","article-title":"The Need of Antimicrobial Stewardship in Post-Operative Infectious Complications of Abdominal Surgery","volume":"38","author":"Obst","year":"2022","journal-title":"Visc. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/cc8877","article-title":"Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis","volume":"14","author":"Augustin","year":"2010","journal-title":"Crit. Care"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Steinbach, C.L., T\u00f6pper, C., Adam, T., and Kees, M.G. (2015). Spectrum adequacy of antibiotic regimens for secondary peritonitis: A retrospective analysis in intermediate and intensive care unit patients. Ann. Clin. Microbiol. Antimicrob., 14.","DOI":"10.1186\/s12941-015-0110-4"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s15010-009-8249-6","article-title":"The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis","volume":"37","author":"Weel","year":"2009","journal-title":"Infection"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13054-015-0789-9","article-title":"Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitis","volume":"19","author":"Montravers","year":"2015","journal-title":"Crit. Care"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Maseda, E., Ram\u00edrez, S., Picatto, P., Pel\u00e1ez-Pel\u00e1ez, E., Garc\u00eda-Bernedo, C., Ojeda-Betancur, N., Aguilar, G., For\u00e9s, B., Solera-Mar\u00edn, J., and Alia\u00f1o-Pi\u00f1a, M. (2019). Critically ill patients with community-onset intraabdominal infections: Influence of healthcare exposure on resistance rates and mortality. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223092"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.00265-10","article-title":"Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"54","author":"Hawser","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11597960-000000000-00000","article-title":"Plasmid-mediated resistance in Enterobacteriaceae: Changing landscape and implications for therapy","volume":"72","author":"Schultsz","year":"2012","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use beta-lactam\/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase-producing bacteria?","volume":"54","author":"Perez","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkv441","article-title":"Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam","volume":"71","author":"Reuland","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jama.2018.19345","article-title":"Antibiotics for Ceftriaxone-resistant gram-negative bacterial bloodstream infections","volume":"321","author":"Kahlmeter","year":"2019","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ofab387","DOI":"10.1093\/ofid\/ofab387","article-title":"Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC \u03b2-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)","volume":"8","author":"Stewart","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijantimicag.2018.07.021","article-title":"Beta-lactam\/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: Systematic review and meta-analysis","volume":"52","author":"Sfeir","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"Extended-Spectrum Beta-Lactamases\u2013Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa\/Grupo de Estudio de Infecci\u00f3n Hospitalaria Group. \u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts","volume":"54","author":"Navarro","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"64","author":"Kang","year":"2012","journal-title":"J. Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2147\/IDR.S314241","article-title":"An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of BSIs, cUTIs, and cIAIs caused by enterobacterales in critically ill adult patients","volume":"14","author":"Gatti","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13017-016-0089-y","article-title":"Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA)","volume":"11","author":"Sartelli","year":"2016","journal-title":"World J. Emerg. Surg."},{"key":"ref_53","first-page":"19","article-title":"Deciphering pharmacokinetics and pharmacodynamics of fosfomycin","volume":"32","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107134","DOI":"10.1016\/j.ijantimicag.2024.107134","article-title":"Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience","volume":"63","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23744235.2025.2544828","article-title":"Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane\/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections","volume":"6","author":"Li","year":"2025","journal-title":"Infect. Dis."},{"key":"ref_56","first-page":"e86262","article-title":"The Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem for Intra-abdominal Infections: A Systematic Review and Meta-Analysis","volume":"17","author":"Nouh","year":"2025","journal-title":"Cureus"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"Lok","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: A retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Loeches","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e01964","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-Avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e00449-17","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102598","DOI":"10.1016\/j.jiac.2024.102598","article-title":"Efficacy and safety of ceftazidime-avibactam in combination with metronidazole in Japanese patients with complicated intra-abdominal infection: A phase 3, multicentre, open-label study","volume":"31","author":"Mikamo","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u201317)","volume":"75","author":"Spiliopoulou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"ofaa051","DOI":"10.1093\/ofid\/ofaa051","article-title":"Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Kimbrough, J.H., Winkler, M.L., Mendes, R.E., and Castanheira, M. (2025). Activity of \u03b2-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019\u20132023). Antibiotics, 14.","DOI":"10.3390\/antibiotics14060544"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients with Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Walkty, A., Karlowsky, J.A., Lagac\u00e9-Wiens, P.R.S., Baxter, M.R., Adam, H.J., Bay, D.C., and Zhanel, G.G. (2023). Moving towards a standardized definition of antimicrobial resistance: A comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016\u20132021). Diagn. Microbiol. Infect. Dis., 108.","DOI":"10.1016\/j.diagmicrobio.2023.116130"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkab306","article-title":"Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime\/avibactam, meropenem\/vaborbactam and comparators against these isolates","volume":"76","author":"Castanheira","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e02408-19","DOI":"10.1128\/AAC.02408-19","article-title":"Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., Guo, Y., and Hu, F. (2023). Klebsiella pneumoniae carbapenemase variants: The new threat to global public health. Clin. Microbiol. Rev., 36.","DOI":"10.1128\/cmr.00008-23"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e0044722","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: An Evolutionary Overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Li, S., Feng, X., Li, M., and Shen, Z. (2023). In vivo adaptive antimicrobial resistance in Klebsiella pneumoniae during antibiotic therapy. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1159912"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Meng, R., Guan, X., Sun, L., Fei, Z., Li, Y., Luo, M., Ma, A., and Li, H. (2022). The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.935343"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., van Duin, D., and Clancy, C.J. (2023). Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin. Infect. Dis., ciad428.","DOI":"10.1093\/cid\/ciad428"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: The tetracyclines strike back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1093\/ofid\/ofy210.1634","article-title":"Efficacy of eravacycline in secondary bacteremia: A post hoc analysis of two phase 3 studies of complicated intra-abdominal infection","volume":"5","author":"Lawrence","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: A multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jiph.2023.06.009","article-title":"Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study","volume":"16","author":"Onorato","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol versus colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: A retrospective, propensity-score adjusted. Monocentric Cohort Study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Giurazza, R., Mazza, M.C., Andini, R., Sansone, P., Pace, M.C., and Durante-Mangoni, E. (2021). Emerging treatment options for multi-drug-resistant bacterial infections. Life, 11.","DOI":"10.3390\/life11060519"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Domingues, S., Lima, T., Saavedra, M.J., and Da Silva, G.J. (2023). An overview of cefiderocol\u2019s therapeutic potential and underlying resistance mechanisms. Life, 13.","DOI":"10.3390\/life13071427"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.4629","article-title":"Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens","volume":"44","author":"Bleick","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: Report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: A Phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13054-019-2581-8","article-title":"Impact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care-an analysis of the OUTCOMEREA database","volume":"23","author":"Morvan","year":"2019","journal-title":"Crit. Care"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/clinids\/15.1.72","article-title":"Enterococcal infections in surgical patients: The mystery continues","volume":"15","author":"Nichols","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/jac\/dkr308","article-title":"Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit","volume":"66","author":"Dupont","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Vallicelli, C., Santandrea, G., Sartelli, M., Coccolini, F., Ansaloni, L., Agnoletti, V., Bravi, F., and Catena, F. (2022). Sepsis Team Organizational Model to Decrease Mortality for Intra-Abdominal Infections: Is Antibiotic Stewardship Enough?. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111460"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg. Infect."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/sur.2017.121","article-title":"Does isolation of enterococcus affect outcomes in intra-abdominal infections?","volume":"18","author":"Sanders","year":"2017","journal-title":"Surg. Infect."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"ofy339","DOI":"10.1093\/ofid\/ofy339","article-title":"The role of ertapenem for the treatment of complicated intra-abdominal infections with a positive culture for Enterococcus faecalis","volume":"6","author":"Fabre","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10096-003-1078-0","article-title":"Are there patients with peritonitis who require empiric therapy for enterococcus?","volume":"23","author":"Harbarth","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhin.2023.09.008","article-title":"Epidemiology and outcomes of vancomycin-resistant enterococcus infections: A systematic review and meta-analysis","volume":"141","author":"Eichel","year":"2023","journal-title":"J. Hosp. Infect."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The surgical infection society revised guidelines on the management of intra-abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg. Infect."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Cairns, K.A., Udy, A.A., Peel, T.N., Abbott, I.J., Dooley, M.J., and Peleg, A.Y. (2023). Therapeutics for vancomycin-resistant enterococcal bloodstream infections. Clin. Microbiol. Rev., 36.","DOI":"10.1128\/cmr.00059-22"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1128\/AAC.48.5.1441-1453.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue","volume":"48","author":"Derendorf","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","article-title":"Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability","volume":"44","author":"Pea","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/49.1.121","article-title":"Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections","volume":"49","author":"Buijk","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/11319370-000000000-00000","article-title":"Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis","volume":"49","author":"Lefeuvre","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/sj.clpt.6100312","article-title":"Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock","volume":"83","author":"Karjagin","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jac\/dkz407","article-title":"Serum and peritoneal exudate concentrations after high doses of \u03b2-lactams in critically ill patients with severe intra-abdominal infections: An observational prospective study","volume":"75","author":"Leon","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/cc7774","article-title":"Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock\u2014Does the dose matter?","volume":"13","author":"Pea","year":"2009","journal-title":"Crit. Care"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/AAC.00329-06","article-title":"Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection","volume":"50","author":"Lau","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A Multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijantimicag.2008.10.025","article-title":"Clinical cure of ventilator-associated pneumonia treated with piperacillin\/tazobactam administered by continuous or intermittent infusion","volume":"33","author":"Lorente","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: The MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.2023.6483","article-title":"Do prolonged infusions of \u03b2-lactam antibiotics improve outcomes in critically ill patients with sepsis?","volume":"330","author":"Shappell","year":"2023","journal-title":"JAMA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"717","DOI":"10.7326\/0003-4819-124-8-199604150-00003","article-title":"Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis","volume":"124","author":"Hatala","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"ref_123","first-page":"576","article-title":"Antimicrobial Stewardship Impact on the Treatment of Intra-abdominal Infections in the Surgical Intensive Care Unit","volume":"26","author":"Peterson","year":"2025","journal-title":"Surg. Infect."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","author":"Sawyer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(22)02588-0","article-title":"2 days versus 5 days of postoperative antibiotics for complex appendicitis: A pragmatic, open-label, multicentre, non-inferiority randomised trial","volume":"401","author":"Boerma","year":"2023","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00134-018-5088-x","article-title":"Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: The DURAPOP randomised clinical trial","volume":"44","author":"Montravers","year":"2018","journal-title":"Intensive Care Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jss.2020.10.029","article-title":"Optimal antibiotic duration for bloodstream infections secondary to intraabdominal infection","volume":"260","author":"Patel","year":"2021","journal-title":"J. Surg. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/sur.2015.130","article-title":"Duration of antimicrobial therapy in treating complicated intra-abdominal infections: A comprehensive review","volume":"17","author":"Sartelli","year":"2016","journal-title":"Surg. Infect."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/sur.2017.084","article-title":"Longer-duration antimicrobial therapy does not prevent treatment failure in high-risk patients with complicated intra-abdominal infections","volume":"18","author":"Hassinger","year":"2017","journal-title":"Surg. Infect."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1164\/rccm.200708-1238OC","article-title":"Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial","volume":"177","author":"Nobre","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1097\/CCM.0b013e31828e969f","article-title":"Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: A randomized trial","volume":"41","author":"Oliveira","year":"2013","journal-title":"Crit. Care Med."},{"key":"ref_132","first-page":"382","article-title":"Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial","volume":"33","author":"Qu","year":"2012","journal-title":"Saudi Med. J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00423-008-0432-1","article-title":"Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study","volume":"394","author":"Schroeder","year":"2009","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201408-1483OC","article-title":"Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial","volume":"190","author":"Shehabi","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Huang, T.S., Huang, S.S., Shyu, Y.C., Lee, C.H., Jwo, S.C., Chen, P.J., and Chen, H.Y. (2014). A procalcitonin-based algorithm to guide AB therapy in secondary peritonitis following emergency surgery: A prospective study with propensity score matching analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090539"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jcrc.2014.12.014","article-title":"Procalcitonin-guided therapy may reduce length of AB treatment in intensive care unit patients with secondary peritonitis: A multicenter retrospective study","volume":"30","author":"Maseda","year":"2015","journal-title":"J. Crit. Care"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3457614","DOI":"10.1155\/2017\/3457614","article-title":"Procalcitonin-guided ABs after surgery for peritonitis: A randomized Controlled Study","volume":"2017","author":"Slieker","year":"2017","journal-title":"Gastroenterol. Res. Pract."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/11\/1127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:26:11Z","timestamp":1762514771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/11\/1127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":137,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["antibiotics14111127"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14111127","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}